TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16431252

Group type: EXPERIMENTAL
Intervention: Methylprednisolone alternated with a cytotoxic drug every other month for 6 months (group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Synthetic adrenocorticotropic hormone administered twice a week for 1 year (group B)
Number of subjects: 32
Study: 15571446

Group type: EXPERIMENTAL
Intervention: Alcohol-moderate (.70 gm alcohol/kg body weight)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alcohol-low (.35 gm alcohol/kg body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Perceived intoxication
Number of subjects: 60
Study: 11694408

Group type: EXPERIMENTAL
Intervention: rHuEpo and G-CSF
Number of subjects: 18

Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 18
Study: 9212116

Group type: EXPERIMENTAL
Intervention: Milrinone 50 microg/kg intravenously (n = 8)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Milrinone 50 microg/kg + 0.5 microg x kg(‐1) x min(‐1) (n = 10)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Milrinone 75 microg/kg + 0.75 microg x kg(‐1) x min(‐1) (n = 9)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 37
Study: 7965243

Group type: EXPERIMENTAL
Intervention: Mail with prepaid postage
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Mail
Number of subjects: 146

Group type: COMPARATOR
Intervention: Hand delivery
Number of subjects: 146
Study: 30176174

Group type: EXPERIMENTAL
Intervention: Partnership including an industry partner, university partner, and NGO partner with COI-mitigation processes (arm's-length process, independent advisory board, open data commitment)
Number of subjects: 2339

Group type: EXPERIMENTAL
Intervention: Zero, one, two, or three COI-mitigation procedures in a partnership of a university and either an NGO or industry partner
Number of subjects: 2339
Study: 29420766

Group type: EXPERIMENTAL
Intervention: EZ‐IO® System with proximal tibia approach
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: EZ‐IO® System with proximal humerus approach
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: EZ‐IO® System
Number of subjects: 77
Study: 27687403

Group type: EXPERIMENTAL
Intervention: Streamlined liner of pharyngeal airway (SLIPA) in nonparalyzed patients (group NR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Streamlined liner of pharyngeal airway (SLIPA) in paralyzed patients (group R)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Streamlined liner of pharyngeal airway (SLIPA)
Number of subjects: 80
Study: 25405478

Group type: EXPERIMENTAL
Intervention: Statin Outreach Support (SOS) intervention
Number of subjects: 7586

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7586
Study: 22505248

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (six times per week)
Number of subjects: 6276

Group type: COMPARATOR
Intervention: Standard hemodialysis (three times per week)
Number of subjects: 6276
Study: 20304348

Group type: EXPERIMENTAL
Intervention: parecoxib 20 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: parecoxib 40 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: normal saline (Group NS)
Number of subjects: 150
Study: 17768687

Group type: EXPERIMENTAL
Intervention: Work-oriented vocational therapy group
Number of subjects: 227

Group type: COMPARATOR
Intervention: Creativity-oriented ergotherapy group
Number of subjects: 227
Study: 16336326

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (MVAC/MVEC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (observation only)
Number of subjects: 49
Study: 12953657

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200 mg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 33
Study: 10848646

Group type: EXPERIMENTAL
Intervention: Short programme (SP) - trained every day for 2 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Long programme (LP) - trained over a 6-week period with a 2-day rest period after each training session
Number of subjects: 10
Study: 8872623

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at different force levels (5, 10, 20, 40, and 60% MVC)
Number of subjects: 11
Study: 1322162

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amiloride 10 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6528870

Group type: EXPERIMENTAL
Intervention: Self-regulation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Physician regulation
Number of subjects: 108
Study: 31830258

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100,000 IU (n=25)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (n=23)
Number of subjects: 48
Study: 29799099

Group type: EXPERIMENTAL
Intervention: CTC 100 mg
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: CTC 150 mg
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: CTC 200 mg
Number of subjects: 334

Group type: COMPARATOR
Intervention: Tramadol 100 mg
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study: 27811556

Group type: EXPERIMENTAL
Intervention: Duloxetine (mean dosage 44.4 mg/d, range 20-60 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sertraline (mean dosage 123.8 mg/d, range 50-200 mg/d)
Number of subjects: 46
Study: 24533896

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Fluoxetine (normal pH subgroup)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Omeprazole (normal pH subgroup)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (normal pH subgroup)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Fluoxetine (abnormal pH subgroup)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Omeprazole (abnormal pH subgroup)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (abnormal pH subgroup)
Number of subjects: 144
Study: 22902194

Group type: EXPERIMENTAL
Intervention: Side‐posture SMT (n = 30)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cavitating joints
Number of subjects: 40

Group type: COMPARATOR
Intervention: Side‐posture positioning (SPP, n = 10)
Number of subjects: 40
Study: 19155748

Group type: EXPERIMENTAL
Intervention: Melatonin (8.5 mg immediate release and 1.5 mg sustained release)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 17484223

Group type: COMPARATOR
Intervention: Inactivated Polio Vaccine (IPV)
Number of subjects: 9544

Group type: EXPERIMENTAL
Intervention: Measles Vaccine (MV)
Number of subjects: 9544

Group type: EXPERIMENTAL
Intervention: IPV after receiving MV at 9 months or later
Number of subjects: 9544

Group type: EXPERIMENTAL
Intervention: DTP vaccination status at enrollment
Number of subjects: 9544

Group type: EXPERIMENTAL
Intervention: Measles Vaccine (MV) as the most recent vaccine
Number of subjects: 9544
Study: 15492297

Group type: EXPERIMENTAL
Intervention: 16-slice MDCT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 16-slice MDCT (restricted to proximal coronary segments)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 16-slice MDCT (restricted to segments with excellent image quality)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 16-slice MDCT (patient-based model)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Coronary calcification
Number of subjects: 33
Study: 12001536

Group type: EXPERIMENTAL
Intervention: On-pump CABG (group I)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Off-pump CABG (group II)
Number of subjects: 106
Study: 9682111

Group type: EXPERIMENTAL
Intervention: lovision 127
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Mentor ORC MemoryLens
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Alcon AcrySof MA30BA
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Allergan PhacoFlex II
Number of subjects: 133
Study: 8025424

Group type: EXPERIMENTAL
Intervention: Belmont 1992
Number of subjects: 2260

Group type: EXPERIMENTAL
Intervention: Wagga Wagga 1992
Number of subjects: 2260

Group type: EXPERIMENTAL
Intervention: Atopic children
Number of subjects: 2260

Group type: EXPERIMENTAL
Intervention: Belmont
Number of subjects: 2260

Group type: EXPERIMENTAL
Intervention: Wagga Wagga
Number of subjects: 2260
Study: 2505996

Group type: EXPERIMENTAL
Intervention: Antacid suspension (10 ml)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No antacid
Number of subjects: 8
Study: 963493

Group type: EXPERIMENTAL
Intervention: Nimorazole (300 mg twice daily for 7 days)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Metronidazole (200 mg three times a day for 7 days)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Antigonococcal therapy (one-day treatment with ampicillin or single-dose therapy with doxycycline)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Antitrichomonal therapy
Number of subjects: 112
Study: 31694611

Group type: EXPERIMENTAL
Intervention: Hybrid-ECT (3 ECT sessions followed by LCE sessions, approximately 2.8 joules per session)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional ECT (control group)
Number of subjects: 112
Study: 28249141

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 405

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 405
Study: 26527789

Group type: COMPARATOR
Intervention: Chemoradiotherapy boost (arm A)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Surgery (arm B)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Overall (all patients)
Number of subjects: 246
Study: 24352394

Group type: EXPERIMENTAL
Intervention: Extraction of right and left maxillary first premolars (G1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-extraction (G2)
Number of subjects: 12
Study: 21440872

Group type: EXPERIMENTAL
Intervention: HSS plus furosemide (250 mg) and light sodium restriction (120 mmol)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Furosemide (250 mg) alone with low sodium diet (80 mmol)
Number of subjects: 133
Study: 19806919

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eplerenone multiple doses 50 mg
Number of subjects: 0
Study: 16958566

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 12975670

Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: M-VAC combination chemotherapy
Number of subjects: 0
Study: 10919743

Group type: EXPERIMENTAL
Intervention: 10 g of flaxseed
Number of subjects: 16

Group type: COMPARATOR
Intervention: 28 g of wheat bran
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 g of flaxseed plus 28 g of wheat bran
Number of subjects: 16

Group type: COMPARATOR
Intervention: No flaxseed or wheat bran
Number of subjects: 16
Study: 8829030

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 0
Study: 1416236

Group type: EXPERIMENTAL
Intervention: Heavy (S2) Alastik separators
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (separator placed and removed)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no separator)
Number of subjects: 21
Study: 2859739

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propranolol 80 mg (control)
Number of subjects: 30
Study: 30130991

Group type: EXPERIMENTAL
Intervention: Group B: 30‐min seminar about the 'One Stretch' exercise
Number of subjects: 4767

Group type: EXPERIMENTAL
Intervention: Group C: B + physical and psychological approaches to LBP treatment
Number of subjects: 4767

Group type: COMPARATOR
Intervention: Group A: Control group
Number of subjects: 4767
Study: 29681489

Group type: EXPERIMENTAL
Intervention: Video-assisted fundoscopy
Number of subjects: 101
Study: 28049599

Group type: EXPERIMENTAL
Intervention: Bileaflet aortic valve replacement
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement (MVR)
Number of subjects: 39
Study: 26683621

Group type: EXPERIMENTAL
Intervention: Uterine tone assessment by a skilled birth attendant (midwife)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Uterine tone self-assessment
Number of subjects: 800
Study: 24461758

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing
Number of subjects: 47
Study: 22017169

Group type: EXPERIMENTAL
Intervention: Osteopontin levels in men (mean ± SD: 60.7 ± 15.6 μg/mL)
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Osteopontin levels in women (mean ± SD: 51.7 ± 16.0 μg/mL)
Number of subjects: 1817
Study: 18452361

Group type: EXPERIMENTAL
Intervention: Passive maxillary plates during the first year of life (Group IO+)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No intervention (Group IO-)
Number of subjects: 54
Study: 16541086

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 28
Study: 12712082

Group type: EXPERIMENTAL
Intervention: Cytologic testing
Number of subjects: 117

Group type: COMPARATOR
Intervention: Histologic interpretation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cytologic/histologic pairs
Number of subjects: 117

Group type: COMPARATOR
Intervention: Progression to high-grade lesions
Number of subjects: 117
Study: 10757134

Group type: EXPERIMENTAL
Intervention: 0.62 g/kg of alcohol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 9282804

Group type: EXPERIMENTAL
Intervention: 1 g of acetazolamide (Diamox) intravenous injection
Number of subjects: 50
Study: 8350585

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 21

Group type: COMPARATOR
Intervention: Positioning changes (prone/supine)
Number of subjects: 21
Study: 2881901

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29226816

Group type: EXPERIMENTAL
Intervention: Intravenous furosemide (IV), mean dose: 123 ± 47 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Subcutaneous furosemide (SC), fixed dose of 80 mg over 5 h
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravenous furosemide (IV)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Subcutaneous furosemide (SC)
Number of subjects: 41
Study: 27938870

Group type: EXPERIMENTAL
Intervention: Structured antenatal programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditorium-based lectures
Number of subjects: 0
Study: 24923685

Group type: EXPERIMENTAL
Intervention: 91-day extended regimen combined oral contraceptive (150 μg levonorgestrel [LNG]/30 μg ethinylestradiol [EE] for 84 days, followed by 10 μg EE for seven days)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Traditional 21/7 regimen (21 days 150 μg LNG/30 μg EE)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Traditional 21/7 regimen (150 μg desogestrel [DSG]/30 μg EE)
Number of subjects: 187
Study: 24315267

Group type: EXPERIMENTAL
Intervention: Music provided by an iPod
Number of subjects: 25

Group type: COMPARATOR
Intervention: No music
Number of subjects: 25
Study: 21702861

Group type: EXPERIMENTAL
Intervention: Repositioning every three hours at night using the 30° tilt (experimental group)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Routine prevention (six-hourly repositioning using 90° lateral rotation) (control group)
Number of subjects: 213
Study: 18840106

Group type: EXPERIMENTAL
Intervention: 1.5 microg/kg fentanyl injected over 2 s
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: 1.5 microg/kg fentanyl injected over 5 s
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: 1.5 microg/kg fentanyl injected over 10 s
Number of subjects: 476

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 476
Study: 17070152

Group type: EXPERIMENTAL
Intervention: Community hospital (n = 305)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Regional hospital (n = 304)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Excluded high-risk PCI patients
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 609
Study: 12568305

Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone (GS group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Granisetron alone (G group)
Number of subjects: 50
Study: 10898118

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.8 mg
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Cerivastatin 0.4 mg
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1170
Study: 9352727

Group type: EXPERIMENTAL
Intervention: Intensive neurodevelopmental therapy (NDT) plus casting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular occupational therapy (OT) program
Number of subjects: 0
Study: 8470384

Group type: EXPERIMENTAL
Intervention: Telephone reminders attempted the evening before scheduled visits (intervention group).
Number of subjects: 497

Group type: COMPARATOR
Intervention: No telephone reminders (control group).
Number of subjects: 497
Study: 3013704

Group type: EXPERIMENTAL
Intervention: High carbohydrate, high fibre diet (55% of total energy) for six weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low carbohydrate diet (35% of total energy) for six weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High carbohydrate, high fibre diet (55% of total energy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low carbohydrate diet (35% of total energy)
Number of subjects: 0
Study: 30354590

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents (BP-SES)
Number of subjects: 2902

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents (DP-EES)
Number of subjects: 2902
Study: 27282262

Group type: EXPERIMENTAL
Intervention: Sampling bottle
Number of subjects: 1701

Group type: COMPARATOR
Intervention: Conventional container
Number of subjects: 1701
Study: 24986270

Group type: EXPERIMENTAL
Intervention: Cure‐allergic‐rhinitis Syrup (CS)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Yu‐ping‐feng San (YS)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 22778123

Group type: EXPERIMENTAL
Intervention: Educational intervention targeting general practitioners (practice audit with personalized automated feedback, printed educational material, and newsletters over 2 years)
Number of subjects: 21762

Group type: COMPARATOR
Intervention: Control group (practice audit without individualized feedback and newsletters without educational material)
Number of subjects: 21762

Group type: EXPERIMENTAL
Intervention: Educational intervention targeting general practitioners
Number of subjects: 21762
Study: 20540806

Group type: EXPERIMENTAL
Intervention: Real acupuncture (2 times a week for a total of 12 sessions over 6 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture (same frequency and duration as real acupuncture)
Number of subjects: 0
Study: 18677276

Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position (RTP) at 10 degrees during surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supine position (control group)
Number of subjects: 60
Study: 20801498

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 10285

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10285
Study: 15663667

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 589

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 589
Study: 12419747

Group type: EXPERIMENTAL
Intervention: Topotecan plus gemcitabine (Topotecan initial dose 0.5 mg/m2 daily for days 1-5, gemcitabine 800 mg/m2 on day 1 and 600 mg/m2 on day 8)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Topotecan plus gemcitabine
Number of subjects: 21
Study: 9869553

Group type: EXPERIMENTAL
Intervention: Clinical autonomic symptoms
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Absent ankle reflexes
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Electrophysiologic changes of an axonal neuropathy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Demyelinating neuropathy
Number of subjects: 138
Study: 7635028

Group type: EXPERIMENTAL
Intervention: Mesalazine enema (Pentasa-Yamanouchi Pharma)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral formulations of mesalazine
Number of subjects: 0
Study: 2658438

Group type: EXPERIMENTAL
Intervention: Insulin coma (IC) after pharmacotherapy with mageptil, chlorpromazine, melipramine
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Insulin coma (IC) after pharmacotherapy with haloperidol, triphtazin, amitriptyline
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Insulin coma (IC) after benzodiazepines
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Insulin coma (IC) therapy
Number of subjects: 172

Group type: COMPARATOR
Intervention: Insulin coma (IC) in drug-free patients
Number of subjects: 172
Study: 30916655

Group type: EXPERIMENTAL
Intervention: Serious game (Tobbstop) used for 3 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no serious game)
Number of subjects: 42
Study: 28622178

Group type: EXPERIMENTAL
Intervention: Dural Puncture Epidural (DPE) with 0.125% bupivacaine and 50 μg fentanyl
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lumbar Epidural (LE) with 0.125% bupivacaine and 50 μg fentanyl
Number of subjects: 80
Study: 26951210

Group type: EXPERIMENTAL
Intervention: What Were We Thinking (WWWT) programme
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 25262346

Group type: EXPERIMENTAL
Intervention: Tai-chi intervention for 12 weeks
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Exercise intervention for 12 weeks
Number of subjects: 153

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 153